Condition
Eltrombopag
Total Trials
5
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
P 2 (2)
P 3 (1)
P 4 (1)
Trial Status
Unknown2
Completed2
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT04600960Phase 2Recruiting
Eltrombopag for Chemotherapy-induced Thrombocytopenia
NCT03515096Phase 3CompletedPrimary
Eltrombopag vs. rhTPO to Increase Platelet Level After HSCT
NCT03243656Phase 4CompletedPrimary
Eltrombopag & Cyclosporine in Children With Sever Aplastic Anemia
NCT03902041Unknown
The Prospective Randomized Controlled Study of Eltrombopag on Hematopoietic Reconstruction After Allogeneic HSCT
NCT03701217Phase 2UnknownPrimary
Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in AML
Showing all 5 trials